( ng the treatment groups (percentage of ...)Progenics Announces Positive Results in Clinical Trial of Novel HIV,Therapy,Health

                         Placebo    0.5 mg/kg   2.0 mg/kg   5.0 mg/kg
(n=9)      (n=10)      (n=10)      (n=10)
----------------------------------------------------------------------
Mean maximum log10       -0.39       -0.58       -1.20        -1.83
change in HIV RNA                   (p=0.34)   (p=0.0002)  (p<0.0001)
----------------------------------------------------------------------
Mean log10 change in                 -0.37       -1.04        -1.70
HIV RNA 9 days post-     -0.13      (p=0.26)   (p=0.0001)  (p<0.0001)
treatment
----------------------------------------------------------------------
Number of patients
with a =>1.0 log10        0/9         1/10        6/10        10/10
decrease in HIV RNA                  (p=1.0)    (p=0.011)  (p<0.0001)
at any time
----------------------------------------------------------------------
* P values are from an analysis of variance model (ANOVA), pairwise
two-sided t tests comparing each treatment group to placebo after the
overall F test was found to be statistically significant. Log10
changes in HIV RNA are calculated relative to baseline.

In this study, PRO 140 was generally well tolerated and no drug-related serious adverse events were reported. A more detailed discussion of the study results is planned for an upcoming scientific conference.

"These clinical findings with PRO 140 in HIV infection represent a major achievement for Progenics and a further strengthening of our drug pipeline," said Paul J. Maddon, M.D., Ph.D., Progenics' Founder, Chief Executive Officer and Chief Science Officer, and who played a significant part in the discovery of CCR5's role in HIV infection. "As an HIV/AIDS researcher for more than two decades, I was particularly gratified to see these results from our propri
'"/>